Tulis DA - Search Results

1

Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells.

Mendelev NN, Williams VS, Tulis DA. Mendelev NN, et al. Among authors: tulis da. J Cardiovasc Pharmacol. 2009 Feb;53(2):121-31. doi: 10.1097/FJC.0b013e31819715c4. J Cardiovasc Pharmacol. 2009. PMID: 19188837 Free PMC article.

2

Salutary properties of YC-1 in the cardiovascular and hematological systems.

Tulis DA. Tulis DA. Curr Med Chem Cardiovasc Hematol Agents. 2004 Oct;2(4):343-59. doi: 10.2174/1568016043356200. Curr Med Chem Cardiovasc Hematol Agents. 2004. PMID: 15320784 Review.

3

Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside.

Jackson EB Jr, Mukhopadhyay S, Tulis DA. Jackson EB Jr, et al. Among authors: tulis da. Curr Vasc Pharmacol. 2007 Jan;5(1):1-14. Curr Vasc Pharmacol. 2007. PMID: 17266609 Review.

4

YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells.

Liu XM, Peyton KJ, Mendelev NN, Wang H, Tulis DA, Durante W. Liu XM, et al. Among authors: tulis da. Mol Pharmacol. 2009 Jan;75(1):208-17. doi: 10.1124/mol.108.048314. Epub 2008 Oct 15. Mol Pharmacol. 2009. PMID: 18923065 Free PMC article.

5

Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Tulis DA. Tulis DA. Am J Ther. 2008 Nov-Dec;15(6):551-64. doi: 10.1097/MJT.0b013e318140052f. Am J Ther. 2008. PMID: 19127140 Free PMC article. Review.

6

The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects.

Keswani AN, Peyton KJ, Durante W, Schafer AI, Tulis DA. Keswani AN, et al. Among authors: tulis da. J Cardiovasc Pharmacol Ther. 2009 Jun;14(2):116-24. doi: 10.1177/1074248409333266. Epub 2009 Apr 2. J Cardiovasc Pharmacol Ther. 2009. PMID: 19342499 Free PMC article.

7

The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways.

Joshi CN, Martin DN, Fox JC, Mendelev NN, Brown TA, Tulis DA. Joshi CN, et al. Among authors: tulis da. J Pharmacol Exp Ther. 2011 Nov;339(2):394-402. doi: 10.1124/jpet.111.183400. Epub 2011 Aug 8. J Pharmacol Exp Ther. 2011. PMID: 21825001 Free PMC article.

8

Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.

Adderley SP, Joshi CN, Martin DN, Tulis DA. Adderley SP, et al. Among authors: tulis da. Front Pharmacol. 2012 Feb 7;3:10. doi: 10.3389/fphar.2012.00010. eCollection 2012. Front Pharmacol. 2012. PMID: 22347188 Free PMC article.

9

AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury.

Stone JD, Narine A, Shaver PR, Fox JC, Vuncannon JR, Tulis DA. Stone JD, et al. Among authors: tulis da. Am J Physiol Heart Circ Physiol. 2013 Feb 1;304(3):H369-81. doi: 10.1152/ajpheart.00446.2012. Epub 2012 Nov 30. Am J Physiol Heart Circ Physiol. 2013. PMID: 23203966 Free PMC article.

10

AMP-activated protein kinase inhibits transforming growth factor-β-mediated vascular smooth muscle cell growth: implications for a Smad-3-dependent mechanism.

Stone JD, Holt AW, Vuncannon JR, Brault JJ, Tulis DA. Stone JD, et al. Among authors: tulis da. Am J Physiol Heart Circ Physiol. 2015 Oct;309(8):H1251-9. doi: 10.1152/ajpheart.00846.2014. Epub 2015 Aug 14. Am J Physiol Heart Circ Physiol. 2015. PMID: 26276823 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters